These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22351688)

  • 1. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.
    Wu J; Lorusso PM; Matherly LH; Li J
    Clin Cancer Res; 2012 Apr; 18(7):2066-79. PubMed ID: 22351688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
    Graham RA; Lum BL; Cheeti S; Jin JY; Jorga K; Von Hoff DD; Rudin CM; Reddy JC; Low JA; Lorusso PM
    Clin Cancer Res; 2011 Apr; 17(8):2512-20. PubMed ID: 21300760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.
    Wu J; Wiegand R; LoRusso P; Li J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1537-43. PubMed ID: 21497565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
    Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
    Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
    Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
    Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
    Gounder MM; Rosenbaum E; Wu N; Dickson MA; Sheikh TN; D'Angelo SP; Chi P; Keohan ML; Erinjeri JP; Antonescu CR; Agaram N; Hameed MR; Martindale M; Lefkowitz RA; Crago AM; Singer S; Tap WD; Takebe N; Qin LX; Schwartz GK
    Clin Cancer Res; 2022 Apr; 28(8):1586-1594. PubMed ID: 35110418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding in antiretroviral therapies.
    Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
    LoConte NK; Razak AR; Ivy P; Tevaarwerk A; Leverence R; Kolesar J; Siu L; Lubner SJ; Mulkerin DL; Schelman WR; Deming DA; Holen KD; Carmichael L; Eickhoff J; Liu G
    Invest New Drugs; 2015 Feb; 33(1):169-76. PubMed ID: 25318436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
    Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T
    Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
    Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
    J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs.
    Pike A; Jones B; Markandu R; O'Neill D
    Drug Metab Dispos; 2021 Sep; 49(9):736-742. PubMed ID: 34135088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A; Laheru D; Maitra A; Arcaroli J; Rudek MA; Dasari A; Blatchford PJ; Quackenbush K; Messersmith W
    Invest New Drugs; 2014 Aug; 32(4):739-45. PubMed ID: 24668033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?
    Al-Qassabi J; Tan SPF; Phonboon P; Galetin A; Rostami-Hodjegan A; Scotcher D
    J Pharm Sci; 2024 Jun; 113(6):1664-1673. PubMed ID: 38417790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
    Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
    Richter S; Bedard PL; Chen EX; Clarke BA; Tran B; Hotte SJ; Stathis A; Hirte HW; Razak AR; Reedijk M; Chen Z; Cohen B; Zhang WJ; Wang L; Ivy SP; Moore MJ; Oza AM; Siu LL; McWhirter E
    Invest New Drugs; 2014 Apr; 32(2):243-9. PubMed ID: 23645447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of advanced age and serum α
    Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
    Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
    Nair JS; Sheikh T; Ho AL; Schwartz GK
    Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
    Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
    Li J; Brahmer J; Messersmith W; Hidalgo M; Baker SD
    Invest New Drugs; 2006 Jul; 24(4):291-7. PubMed ID: 16502356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
    Giannetti AM; Wong H; Dijkgraaf GJ; Dueber EC; Ortwine DF; Bravo BJ; Gould SE; Plise EG; Lum BL; Malhi V; Graham RA
    J Med Chem; 2011 Apr; 54(8):2592-601. PubMed ID: 21438527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.